EHR CDS for Alzheimer Disease

Phase-Based Progress Estimates
UCLA Health, Los Angeles, CA
Alzheimer Disease+2 More
EHR CDS - Behavioral
All Sexes
Eligible conditions

Study Summary

This study is evaluating whether a quality improvement intervention can reduce the number of pills prescribed for older adults with Alzheimer's disease.

See full description

Eligible Conditions

  • Alzheimer Disease
  • Dementia of the Alzheimer's Type

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Alzheimer Disease

Study Objectives

This trial is evaluating whether EHR CDS will improve 1 primary outcome and 5 secondary outcomes in patients with Alzheimer Disease. Measurement will happen over the course of 90 days.

12 month time point
Cumulative total of new antipsychotic pill-days prescribed
Number of patients who receive handout
90 days
Death within 90 days after enrollment
Hospitalizations (including psychiatric hospitalizations)
Number of patients with ER visit
Number of patients with hospitalization

Trial Safety

Safety Progress

1 of 3

Other trials for Alzheimer Disease

Trial Design

2 Treatment Groups

1 of 2
EHR CDS tool
1 of 2
Experimental Treatment

This trial requires 117 total participants across 2 different treatment groups

This trial involves 2 different treatments. EHR CDS is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Physicians will not receive intervention and perform duties as usual.
EHR CDS tool
Multi-pronged electronic health record (EHR) clinical decision support (CDS) tool intervention to reduce physician prescriptions of new antipsychotic medications among older adults with ADRD

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 month time point
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 12 month time point for reporting.

Who is running the study

Principal Investigator
C. A. S.
Catherine A. Sarkisian, Principal Investigator
University of California, Los Angeles

Closest Location

UCLA Health - Los Angeles, CA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Physicians who will be eligible to receive the EHR CDS tool intervention include those who provide ambulatory care in the UCLA health system and have newly prescribed antipsychotics (e.g., Quetiepine, Olanzapine, Risperidone, Aripiprazole, Haloperidol, Clozapine) for eligible patients (described below) at the medical center in the last 24 months.
Eligible patients will be enrolled in the study during their first encounter with one of the randomized physicians (see above) during which a new antipsychotic medication order will be initiated. Inclusion criteria for patients will include: 1) having an assigned primary care physician (PCP) and/or assignment to an Accountable Care Organization (ACO) at UCLA Health, and: 2) being part of the health system's EHR-based dementia registry.

Patient Q&A Section

What are common treatments for alzheimer disease?

"There is a variety of treatment for patients with AD; however, many patients use alternative treatments over traditional medical remedies. The more common medications used in patients included acetylcholinesterase inhibitors (AChEIs), such as donepezil, galantamine, or rivastigmine; non-AChEIs, such as memantine; and other medications, such as selective serotonin reuptake inhibitors (SSRIs) and other antidepressants. The incidence of these medications is higher than that of conventional care. There is limited support for alternative medicine therapies; however, further research is needed." - Anonymous Online Contributor

Unverified Answer

Can alzheimer disease be cured?

"Results from a recent clinical trial of our study suggest that the presence of NOS-D as a co-morbidity in AD patients may represent a marker of a worse long-acting form of dementia that warrants further treatment of NOS-Ds." - Anonymous Online Contributor

Unverified Answer

What is alzheimer disease?

"Alzheimer disease is a neurological disorder characterised by declining memory, thinking difficulties and a progressive decrease in the ability to live independently and to function independently of others. There was a shortage of healthcare professionals in China who could diagnose and treat the disease. The condition was not widely recognized, and there was a low awareness of Alzheimer's disease." - Anonymous Online Contributor

Unverified Answer

What causes alzheimer disease?

"At present, there is not a single cause that explains all cases of the disease. The causes are most likely manifold and complex, having to do with genetic, neurological, and environmental factors. The major risk factor is, however, aging.\n" - Anonymous Online Contributor

Unverified Answer

How many people get alzheimer disease a year in the United States?

"1. About 24 percent of Medicare beneficiaries are diagnosed with Alzheimer disease in some 12-year interval, and a comparable proportion have Alzheimer-related diagnoses made in clinical research databases." - Anonymous Online Contributor

Unverified Answer

What are the signs of alzheimer disease?

"In order to help the patient to be familiar with the symptoms of dementia, the health care facilities should ask the patient about their memory, socializing activities, use of medications, and how much they sleep. It is possible to identify the patient's social-cultural risk factors and implement appropriate interventions." - Anonymous Online Contributor

Unverified Answer

What is ehr cds?

"There is a high prevalence of abnormal or non-uniform EEGs as detected in one of every three patients evaluated for epilepsy in a tertiary care hospital in Miami, Florida, as well as in a community setting. Normal EEGs are uncommon. This adds further support to the notion that many patients who complain of epilepsy do not have it, as documented in studies conducted in South Carolina and in a community setting in Florida. Results from a recent paper suggest the need for additional evaluation and treatment to be performed outside of the usual confines of tertiary care epilepsy centers." - Anonymous Online Contributor

Unverified Answer

What is the latest research for alzheimer disease?

"AD Clinical Trial Publications is currently the most authoritative source of current information for all AD Clinical Trials. As the majority of studies on AD clinical trials that received peer reviewer approval report conclusions only in the abstract, we feel that the Abstracts section of this article offers the latest knowledge accessible for the general public." - Anonymous Online Contributor

Unverified Answer

Have there been any new discoveries for treating alzheimer disease?

"While there is a lot of promising research on alzheimer disease treatment, there is no current cure for it. However, there are drug companies working to find one. The only way to find out is with the help of research scientists." - Anonymous Online Contributor

Unverified Answer

Have there been other clinical trials involving ehr cds?

"answer: Clinical trials are generally accepted by the public and health care providers with few known side effects. This may make them an excellent option for treatment; however, they may not be the perfect solution to treat a wide variety of conditions. Therefore, careful consideration of both research methodology and side effects is advised when considering clinical trials." - Anonymous Online Contributor

Unverified Answer

Is ehr cds typically used in combination with any other treatments?

"The study design of the Ehr Study could not detect or assess the effectiveness of Ehr in combination with any form of treatment in patients with AlzHD. Data from a recent study found that the use of a combination of Ehr CDS and any other treatment was not appropriate or beneficial." - Anonymous Online Contributor

Unverified Answer

How does ehr cds work?

"This is a preliminary report on a treatment program for Alzheimer disease with [Cognitive, Functional, Behavioral and Communicative Decline (CFBDC)] components. This treatment program has been completed with [no patient lost to follow-up] and [no adverse event reported]." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Alzheimer Disease by sharing your contact details with the study coordinator.